Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 13/20 | 0.65 |
| ▸ | FDPS | P14324 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14199567 | 0.94 | GGPS1 (0.61) | GGPS1FDPSHDAC4HDAC8BRD4 | |
| SCHEMBL12060536 | 0.88 | GGPS1 (0.72) | GGPS1FDPS | |
| SCHEMBL12060544 | 0.86 | GGPS1 (0.79) | GGPS1FDPS | |
| SCHEMBL12257805 | 0.85 | GGPS1 (0.88) | GGPS1FDPS | |
| SCHEMBL14199566 | 0.82 | GGPS1 (0.68) | GGPS1FDPS | |
| SCHEMBL14199589 | 0.81 | GGPS1 (0.74) | GGPS1FDPS | |
| SCHEMBL14199565 | 0.80 | GGPS1 (0.83) | GGPS1FDPS | |
| SCHEMBL12060601 | 0.80 | GGPS1 (0.83) | GGPS1FDPS | |
| SCHEMBL12060548 | 0.79 | GGPS1 (0.62) | GGPS1FDPSHDAC4HDAC8KAT6A | |
| SCHEMBL12060624 | 0.79 | GGPS1 (0.57) | GGPS1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802641-B1 | BISPHOSPHONATE COMPOUNDS AND METHODS FOR BONE RESORPTION DISEASES, CANCER, BONE PAIN, IMMUNE DISORDERS, AND INFECTIOUS DISEASES | UNIV ILLINOIS (US) | 2011-08-10 | — | — | EP | disclosed |
| US-7745422-B2 | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080318906-A1 | BISPHOSPHONATE COMPOUNDS AND METHODS FOR BONE RESORPTION DISEASES, CANCER, BONE PAIN, IMMUNE DISORDERS, AND INFECTIOUS DISEASES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-12-25 | — | — | US | disclosed |
| US-7358361-B2 | Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318906-A1 | BISPHOSPHONATE COMPOUNDS AND METHODS FOR BONE RESORPTION DISEASES, CANCER, BONE PAIN, IMMUNE DISORDERS, AND INFECTIOUS DISEASES | FDPS, GGPS1, MVD | GGPS1 2/4885FDPS 1/4885HDAC4 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.